Blogs
May 11, 2026
How to read a 10-year Revenue CAGR through four disciplined lenses — illustrated with Titan Biotech FY25 audited numbers (~15% Revenue CAGR, ~29% PAT CAGR, ~103% CFO/OP, Rs.3 Cr borrowings). Educational only.
May 11, 2026
Charlie Munger's 1995 cognitive-bias #14 — the envy tendency — is the single cleanest explanation for India's ₹1.81 lakh crore F&O losses. Titan Biotech FY25's audited numbers read as a corporate version of the same discipline.
May 10, 2026
The Planning Fallacy systematically tricks investors into underestimating time, cost, and risk while overestimating benefits. Indian retail data shows the bias is alive and expensive — median expected returns of 18-22% versus actual Nifty 50 TR of 13.4%. The remedy is Reference-Class Forecasting. Titan Biotech FY25 illustrative numbers — Rs.3 cr borrowings (down 81%), 103% CFO/Operating Profit, paced capex over a decade.
May 10, 2026
Damodaran's identity — Expected Operating-Income Growth = Reinvestment Rate × RoIC — is the single most powerful arithmetic discipline a long-term Indian investor can carry. This educational lesson decodes the formula and applies it to Titan Biotech FY25 audited markers as a positive illustration of disciplined capital allocation.
